Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.

Oncotarget · 2017 · PMC5514957 · PMID 28184031

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

borderline significantp = 0.09so close (0.05 < p ≤ 0.1)

Several other factors had also a borderline significant association with survival: Age with a cut-off value at 60y (74m below 60y vs . 43m above, p = 0.09), History of t-MDS (27m with vs . 44m without, p = 0.09), absence of response to LEN (51m without vs . 37m with, p = 0.06), and prior treatment with HMAs (35m with vs . 45m without, p = 0.14).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.